Featured Articles

  • Are LNPs the new AAV?

    Wednesday, August 27, 2025
    The emergence of nonviral vectors represents an opportunity to propel in vivo gene therapy further into commercial adoption and expand its impact globally. LNPs are poised to become the first commercially approved nonviral vectors for in ... read more

  • Navigating the realities of CAR-T cell oncology trials

    Wednesday, August 20, 2025
    Given the undeniably novel aspect of this new paradigm, however, conducting CAR-T clinical trials presents a unique set of obstacles for sponsors, sites and regulators to carefully navigate. Moreover, the complexity of manufacturing, ... read more

  • Ferring debuts U.S. facility to tackle manufacturing bottlenecks

    Wednesday, August 13, 2025
    Ferring has spared little expense in its efforts to get Adstiladrin to patients, including nearly $500 million in manufacturing investments. read more

  • Cellular rebirth

    Wednesday, August 06, 2025
    After decades of research that hadn’t translated into efficacy in patients and a proliferation of unsubstantiated stem cell science, MSCs seemed stuck in therapeutic purgatory, unable to rise from the pyre and prove their validity. read more

  • MSCs rising

    Wednesday, July 30, 2025
    With MSCs back in the spotlight and a pipeline of mid- and late-stage candidates pushing toward regulatory submission, what looms now is not a question of whether MSCs can deliver, but the challenge of turning decades of insights and ... read more

  • CGT innovation under pressure

    Wednesday, July 23, 2025
    In 2025, a new challenge has taken center stage: A tightening macroeconomic environment that threatens to slow the pace of innovation. read more

  • The state of CAR-T therapy manufacturing

    Wednesday, July 02, 2025
    Emerging cell types are broadening the treatment scope of cell therapy, while automation, PAT and strategic partnerships are addressing manufacturing challenges. Emphasizing the safety of these therapies will improve accessibility and build... read more

  • Unlocking the potential of unconventional T cells

    Wednesday, June 25, 2025
    The cutting edge of cancer research is now expanding beyond conventional T cells to a less-explored, unconventional, unique subset of T cell: mucosal-associated invariant T (MAIT) cells. Engineered MAIT cells may stand to change future ... read more

  • Unpacking cell and gene therapy progress

    Friday, June 13, 2025
    Against a backdrop of historic charm, bold visions for the future of medicine were exchanged as attendees from all over the globe showed up in force to learn, present, collaborate and reconnect on all aspects of cell and gene therapies. read more

  • ISCT 2025 takeaways

    Friday, June 13, 2025
    ISCT is an important event for meeting leaders in the field of cell therapy, exploring the biggest challenges and bottlenecks, and mapping out potential solutions. read more

  • ASGCT takeaways

    Friday, June 13, 2025
    ASGCT is an important meeting to get a lay-of-the-land for the research and early-stage progress for the field of gene therapy, and to help identify the key trends going into the next decade of development for advanced therapies. read more

  • Navigating nuanced CGT clinical trial logistics

    Wednesday, June 11, 2025
    Advances in interactive response technology platforms for drug supply can be highly beneficial when thoughtfully designed to address the unique challenges of CGT trials. This is especially true when these platforms are integrated into a ... read more
Page